两种化疗方案对于TEL-AML1融合基因阳性儿童急性淋巴细胞白血病的疗效比较

doi:10.3969/j.issn.1006-6233.2018.02.007

Abstract
Figure/Table
References
Related Citation (13)

Download: PDF (1328 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective: To compare the difference of clinical efficacy between BCH-2003 program and CCLG-2008 regimen in the diagnosis of acute lymphoblastic leukemia (molecular marker TEL-AML1), so as to provide reference for clinical children to choose appropriate diagnosis and treatment plan according to the actual condition. Methods: From August 2012 to December 2015, 120 cases of children with acute lymphoblastic leukemia who were hospitalized for chemotherapy in our hospital were enrolled in the study. They were treated by BCH-2003 program and CCLG-2008 program. The children in each group were 60 cases, respectively. The molecular biological markers were TEL-AML1. The statistical differences in the recurrence of the two groups, the plasma related biochemical indexes (VEGF, VEGFR, bFGF, MVD), and the clinical efficacy were compared. Results: The changes of VEGF, VEGFR, bFGF and MVD were significantly changed (P<0.05) before and after treatment in the two groups. After treatment, the differences of VEGF, VEGFR and MVD in the two groups were statistically significant (p<0.05). The difference of clinical efficacy between the two groups was statistically significant (P<0.05). The difference of adverse reactions between the two groups was statistically significant (P<0.05). The difference of the risk of recurrence of the two groups was statistically significant (P<0.05), and the difference of the immunophenotype of the two groups was statistically significant (P<0.05). The recurrence of the two groups was compared, and the differences in risk, immune classification and recurrence were statistically significant (all P<0.05). Conclusions: The short term clinical efficacy of the BCH-2003 regimen is better than the CCLG-2008 scheme in the treatment of children with TEL-AML1 fusion gene positive acute lymphoblastic leukemia. However, the incidence of adverse reactions and the severity of relapse in the CCLG-2008 regimen were better than that of the BCH-2003 regimen.

Key words： BCH - 2003 CCLG - 2008 Tel-aml1 fusion gene Children Acute lymphocytic leukemia

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	ZHANG Aiming

Cite this article:

ZHANG Aiming. Comparison of Efficacy of two Chemotherapy Regimens for Acute Lymphoblastic Leukemia in TEL-AML1 Fusion[J]. HeBei Med, 2018, 24(2): 206-211.

URL:

http://www.hbyxzzs.cn/EN/10.3969/j.issn.1006-6233.2018.02.007 OR http://www.hbyxzzs.cn/EN/Y2018/V24/I2/206

[1] 唐艳萍,蔡政民,唐亚梅,等.成人和儿童急性白血病常见融合基因表达的比较[J].广西医学,2017,39(7):952~954.
[2] 吴珺,陆爱东,张乐萍.10岁以上儿童青少年急性淋巴细胞白血病的临床特点及预后分析[J].中国当代儿科杂志,2017,19(6):614~619.
[3] 高静,胡绍燕,卢俊,等.TEL/AML1基因阳性急性淋巴细胞白血病患儿CCLG-ALL-2008方案疗效分析[J].临床儿科杂志,2017,35(5):325~330.
[4] 唐艳萍,蔡政民,唐亚梅,等.表达融合基因的急性B淋巴细胞白血病患者形态学和免疫表型特点[J].现代肿瘤医学,2017,25(7):1097~1100.
[5] Zerra P, Bergsagel J,Keller FG, et al. Maintenance treatment with low-dose mercaptopurine in combination with allopurinol in children with acute lymphoblastic leukemia and mercaptopurine-induced pancreatitis[J]. Pediatr Blood Cancer,2016,63(4):712~715.
[6] 沈伟,韦永琼,于霞,等.儿童急性淋巴细胞白血病MICM检测结果分析[J].检验医学与临床,2016,13(19):2808~2810.
[7] 郑湧智.儿童急性淋巴细胞白血病生物学特征、早期治疗反应及其对预后的影响[D].福建医科大学,2016.
[8] 王青霞,刘征燕,马琳,等.38例儿童急性淋巴细胞白血病染色体结果分析[J].中国优生与遗传杂志,2016,24(5):64+81.
[9] 刘倩妤.儿童急性白血病肿瘤溶解综合征好发因素分析[D].重庆医科大学,2016.
[10] 艾晓非,张岩,石欣荣,等.儿童急性B淋巴细胞白血病中相关融合基因检测结合BIOMED-2标准化Ig基因重排的应用研究[J].中国实验血液学杂志,2016,24(2):352~357.
[11] 轩兴田.55例儿童急性淋巴细胞白血病复发患儿临床特征分析[D].重庆医科大学,2016.
[12] 刘志强,柯江维,乐萍,等.儿童急性淋巴细胞白血病微小残留病的RQ-PCR检测分析[J].实验与检验医学,2015,33(5):542~545.
[13] 赵晓曦,李志刚,崔蕾,等.儿童急性淋巴细胞白血病患者血浆白介素1β检测分析[J].中国小儿血液与肿瘤杂志,2015,20(4):192~197.
[14] 陈音.河南省某综合医院儿童白血病分布特征的回顾性分析[D].郑州大学,2015.
[15] 陈晓娟,邹尧,杨文钰,等.CCLG-ALL2008方案治疗儿童急性淋巴细胞白血病复发患儿的特征分析[J].中国当代儿科杂志,2015,17(4):321~326.
[16] Nabaah A,Jackson MA,Myers A,et al. Mycobacterium chelonae infection involving a percutaneous gastrostomy tube tract in a seven-year-old child with acute lymphoblastic leukemia[J]. Pediatr Infect Dis,2016,35(2):225~226.
[17] 黄鹏丽,许丽亭,江倩,等.血浆miRNA在儿童急性淋巴细胞白血病中表达特点[J].中国小儿血液与肿瘤杂志,2015,20(02):69~73.
[18] 王朦.500例儿童急性白血病临床总结[D].新乡医学院,2015.
[19] Tsepis K, Tragiannidis A, Gombakis N,et al. Early-onset SMART syndrome in an 11-year-old child with acute lymphoblastic leukemia[J].Pediatr Hematol Oncol,2016,8:25~30.
[20] 张小珍,乐萍,霍小春,等.178例儿童急性淋巴细胞白血病细胞与分子遗传学特征研究[J].中国优生与遗传杂志,2014,22(9):33~35,49.
[21] Ghatak N,Trehan A,Bansal D.Financial burden of therapy in families with a child with acute lymphoblastic leukemia:report from north India[J]. Support Care Cancer,2016,24(1):103~108.
[22] 史利欢,郭明发.儿童急性淋巴细胞白血病与TEL-AML1融合基因关联分析[J].中国实用医药,2014,9(17):78~79.
[23] 黄山雅美,贾月萍,刘桂兰,等.不同遗传学异常的急性淋巴细胞白血病患儿微小残留病变化[J].中国当代儿科杂志,2014,16(5):494~498.
[24] 刘芳.122例TEL/AML1(+)儿童急性淋巴细胞白血病的临床特征、疗效及预后因素[D].北京协和医学院,2014.
[25] 王凯玲,梅妍妍,崔蕾,等.两种化疗方案对于TEL-AML1融合基因阳性儿童急性淋巴细胞白血病的疗效比较[J].中国实验血液学杂志,2014,22(2):285-290.
[26] 廉国利,丁玎,吴红艳,等.儿童急性淋巴细胞白血病遗传学特征[J].现代肿瘤医学,2014,22(3):638~640.